Efficacy and Safety Profile of CPX-351 in Secondary Acute Myeloid Leukemia (sAML): A Systematic Review

被引：0
|
作者：
Ibrahim, Ahmed [1 ]
Yousaf, Muhammad Abdullah [1 ]
Ikram, Mariam [2 ]
Khalid, Huma
Anum [3 ]
Safdar, Omar A. [4 ]
Anwer, Zain [5 ]
Faraz, Fatima [1 ]
Rehman, Mohammad [1 ]
Saad, Muhammad [2 ]
机构：
[1] Rawalpindi Med Univ, Rawalpindi, Pakistan
[2] Shifa Int Hosp Ltd, Islamabad, Pakistan
[3] Faisalabad Med Univ, Faisalabad, Pakistan
[4] Univ Arizona, Tucson, AZ USA
[5] Cleveland Clin, Cleveland, OH USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187301
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] CPX 351: A THERAPEUTIC CHALLANGE IN SECONDARY ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE
    Piccioni, A. L.
    Cedrone, M.
    Ceresoli, E.
    Anaclerico, B.
    Borza, P. Anticoli
    Bongarzoni, V.
    Fenu, S.
    Finolezzi, E.
    Crescenzi, S. Leonetti
    Tamburini, A.
    Cudillo, L.
    HAEMATOLOGICA, 2021, 106 (10) : 135 - 135
  • [42] CPX-351 (Vyxeos®) can cause severe rash in acute myeloid leukaemia
    Popper, V.
    Urbantat, R. M.
    Menschel, E.
    Pfeilstoecker, M.
    Forjan, E.
    Nader, A. N.
    Sieghart, C. R.
    Keil, F.
    Koller, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 44 - 44
  • [43] Pooled Clinical Safety Analysis of CPX-351 Versus Conventional Chemotherapy in Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
    Cortes, Jorge E.
    Ryan, Robert J.
    Chiarella, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S214 - S215
  • [44] Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
    Christina Rautenberg
    Friedrich Stölzel
    Christoph Röllig
    Matthias Stelljes
    Verena Gaidzik
    Michael Lauseker
    Oliver Kriege
    Mareike Verbeek
    Julia Marie Unglaub
    Felicitas Thol
    Stefan W. Krause
    Mathias Hänel
    Charlotte Neuerburg
    Vladan Vucinic
    Christian-Friedrich Jehn
    Julia Severmann
    Maxi Wass
    Lars Fransecky
    Jens Chemnitz
    Udo Holtick
    Kerstin Schäfer-Eckart
    Josephine Schröder
    Sabrina Kraus
    William Krüger
    Ulrich Kaiser
    Sebastian Scholl
    Kathrin Koch
    Lea Henning
    Guido Kobbe
    Rainer Haas
    Nael Alakel
    Maximilian-Alexander Röhnert
    Katja Sockel
    Maher Hanoun
    Uwe Platzbecker
    Tobias A. W. Holderried
    Anke Morgner
    Michael Heuser
    Tim Sauer
    Katharina S. Götze
    Eva Wagner-Drouet
    Konstanze Döhner
    Hartmut Döhner
    Christoph Schliemann
    Johannes Schetelig
    Martin Bornhäuser
    Ulrich Germing
    Thomas Schroeder
    Jan Moritz Middeke
    Blood Cancer Journal, 11
  • [45] Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
    Rautenberg, Christina
    Stoelzel, Friedrich
    Roellig, Christoph
    Stelljes, Matthias
    Gaidzik, Verena
    Lauseker, Michael
    Kriege, Oliver
    Verbeek, Mareike
    Unglaub, Julia Marie
    Thol, Felicitas
    Krause, Stefan W.
    Haenel, Mathias
    Neuerburg, Charlotte
    Vucinic, Vladan
    Jehn, Christian-Friedrich
    Severmann, Julia
    Wass, Maxi
    Fransecky, Lars
    Chemnitz, Jens
    Holtick, Udo
    Schaefer-Eckart, Kerstin
    Schroeder, Josephine
    Kraus, Sabrina
    Krueger, William
    Kaiser, Ulrich
    Scholl, Sebastian
    Koch, Kathrin
    Henning, Lea
    Kobbe, Guido
    Haas, Rainer
    Alakel, Nael
    Roehnert, Maximilian-Alexander
    Sockel, Katja
    Hanoun, Maher
    Platzbecker, Uwe
    Holderried, Tobias A. W.
    Morgner, Anke
    Heuser, Michael
    Sauer, Tim
    Goetze, Katharina S.
    Wagner-Drouet, Eva
    Doehner, Konstanze
    Doehner, Hartmut
    Schliemann, Christoph
    Schetelig, Johannes
    Bornhaeuser, Martin
    Germing, Ulrich
    Schroeder, Thomas
    Middeke, Jan Moritz
    BLOOD CANCER JOURNAL, 2021, 11 (10)
  • [46] IN VIVO RAT METABOLISM OF AN ACUTE MYELOID LEUKEMIA (AML) DRUG CPX-351 (CYTARABINE: DAUNORUBICIN) LIPOSOME INJECTION
    Kim-Kang, Heasook
    Yi, Yijun
    Wang, Peter L.
    Tardi, Paul
    Xie, Sherwin
    Mayer, Lawrence
    DRUG METABOLISM REVIEWS, 2015, 47 : 187 - 187
  • [47] Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
    Asghari, Hannah
    Lee, Dasom
    Deutsch, Yehuda E.
    Chan, Onyee
    Al Ali, Najla
    Boisclair, Stephanie
    Terrell, Constance
    Padron, Eric
    Kuykendall, Andrew T.
    List, Alan F.
    Fernandez, Hugo F.
    Lancet, Jeffrey E.
    Sallman, David A.
    Komrokji, Rami S.
    Sweet, Kendra L.
    Talati, Chetasi
    BLOOD, 2019, 134
  • [48] CPX-351 versus cytarabine (CYT) and daunorubicin (DNR) therapy in newly diagnosed AML patients age 60-75: Safety and efficacy in secondary AML (sAML)
    Lancet, J. E.
    Cortes, J. E.
    Kovacsovics, T.
    Hogge, D.
    Kolitz, J. E.
    Tallman, M. S.
    Chiarella, M.
    Louie, A. C.
    Feldman, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] CPX-351: an attractive option for the treatment of older patients with high-risk or secondary acute myeloid leukaemia
    Thomas, Xavier
    Plesa, Adriana
    LANCET HAEMATOLOGY, 2021, 8 (07): : E468 - +
  • [50] Outcomes with CPX-351 versus 7+3 by baseline bone marrow (BM) blast percentage in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia (sAML).
    Ritchie, Ellen K.
    Lin, Tara L.
    Newell, Laura F.
    Stuart, Robert K.
    Solomon, Scott R.
    Stone, Richard M.
    Schiller, Gary J.
    Wieduwilt, Matthew Joseph
    Ryan, Daniel H.
    Ryan, Robert J.
    Chiarella, Michael
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345